Par Drugs and Chemicals Limited

NSE PAR.NS

Par Drugs and Chemicals Limited Operating Income Margin for the year ending March 31, 2024: 57.67%

Par Drugs and Chemicals Limited Operating Income Margin is 57.67% for the year ending March 31, 2024, a 266.26% change year over year. Operating Income Ratio is the proportion of a company's operating income to its net sales, measuring the efficiency of its core business operations in generating profits.

Par Drugs and Chemicals Limited Operating Income Margin for the year ending March 31, 2023 was 15.75%, a -9.94% change year over year.
Par Drugs and Chemicals Limited Operating Income Margin for the year ending March 31, 2022 was 17.48%, a -20.64% change year over year.
Par Drugs and Chemicals Limited Operating Income Margin for the year ending March 31, 2021 was 22.03%, a 81.53% change year over year.
Par Drugs and Chemicals Limited Operating Income Margin for the year ending March 31, 2020 was 12.14%, a 7.06% change year over year.

Key data

Date	Operating Income Margin	EBT Margin	Net Income Margin	EBITDA Margin

NSE: PAR.NS

Par Drugs and Chemicals Limited

CEO	Mr. Jignesh Vallabhbhai Savani
IPO Date	May 30, 2019
Location	India
Headquarters	816, Nilamber Triumph
Employees	122
Sector	Health Care
Industries Pharmaceuticals Chemicals & Advanced Materials Petrochemicals

Description

Par Drugs and Chemicals Limited develops, produces, and sells active pharma ingredients and fine chemicals in India. It offers magnesium salts, dried aluminum hydroxide gel, sodium aluminum silicate, precipitated silica, magnesium silicate, colloidal silicon dioxide, sucralfate USP, and amorphous and blended products. The company also exports its products. Par Drugs and Chemicals Limited was founded in 1982 and is based in Vadodara, India.

Key trends

Past 5 years